Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

Eli Lilly ripped off the bandage when it reported preliminary fourth-quarter results in mid-January, getting the bad news out ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

A lawsuit has been filed in the US claiming that Novo Nordisk and Eli Lilly failed to warn of severe gastrointestinal side effects that can be caused by their incretin mimetic drugs, which are ...

Eli Lilly and Ozempic and Wegovy-maker Novo Nordisk (NVO) are testing their weight-loss drugs' abilities to treat conditions that typically accompany obesity, such as diabetes and sleep apnea.